Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Xenetic Biosciences (3XB0) AI Stock Analysis

0 Followers
DE:3XB0

Xenetic Biosciences

(Munich:3XB0)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue GrowthTTM revenue growth of about 2.22 and continued expansion across prior annual periods indicate increasing commercial activity. If sustained, this top-line momentum can improve operating leverage and support development investment, although profitability is not yet established.
Negative Factors
Persistent LossesTTM net margin of roughly -76%, with EBIT and EBITDA meaningfully negative, shows revenue has not yet scaled enough to cover operating costs. Persistent operating losses constrain internally funded R&D and leave future earnings dependent on successful development and commercialization.

Xenetic Biosciences (3XB0) vs. iShares MSCI Germany ETF (EWG)

-10%-5%0%5%10%15%DE:3XB00.00%EWG+6.88%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 4.37M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-1.6
Beta (1Y)
―
Revenue Growth
―
EPS Growth
―
Country
Germany
Employees
2
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Xenetic Biosciences Business Overview & Revenue Model

Company Description

Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack di...

Xenetic Biosciences Risk Analysis

Xenetic Biosciences disclosed 67 risk factors in its most recent earnings report. Xenetic Biosciences reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Xenetic Biosciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:3XB0 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
APREAPRE43Neutral$6.32M-0.64-44.26%―-99.32%67.31%
HCWBHCWB43Neutral$2.10M-0.01-142.16%―707.02%70.52%

* Healthcare Sector Average

Performance Comparison

-75%-50%-25%0%DE:3XB0ERNAAPREHCWBDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:3XB0 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:3XB0Xenetic Biosciences, Inc.3.860.000.00%
ERNAEterna Therapeutics Inc.1.79-36.21-95.29%
APREAprea Therapeutics, Inc.0.44-0.77-63.64%
HCWBHcw Biologics, Inc.0.80-17.20-95.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.